Share This Page
Drug Price Trends for NDC 51079-0567
✉ Email this page to a colleague
Average Pharmacy Cost for 51079-0567
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| THIORIDAZINE 50 MG TABLET | 51079-0567-20 | 0.73756 | EACH | 2025-11-19 |
| THIORIDAZINE 50 MG TABLET | 51079-0567-01 | 0.73756 | EACH | 2025-11-19 |
| THIORIDAZINE 50 MG TABLET | 51079-0567-20 | 0.72957 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 51079-0567
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 51079-0567
Introduction
The drug with National Drug Code (NDC) 51079-0567 pertains to a specific pharmaceutical product within the context of a highly competitive and evolving marketplace. Accurate market analysis and price projection are vital for stakeholders—including pharmaceutical companies, payers, investors, and healthcare providers—seeking to optimize strategies in product positioning, pricing, and reimbursement negotiations. This comprehensive report delivers an in-depth examination of current market dynamics and future pricing trends governing NDC 51079-0567.
Product Overview and Regulatory Status
NDC 51079-0567 corresponds to a specified formulation, likely a branded or generic drug, with master data reflecting its marketed indications, strength, and packaging. While the exact drug name is not provided here, referencing the NDC suggests its identification within a regulatory framework monitored by the FDA.
The product's regulatory status—whether approved for multiple indications, post-approval supplemental applications, or pending submissions—directly influences its market uptake and price architecture. For existing products, patent exclusivity, orphan drug designation, or biosimilar competition shape the competitive landscape.
Market Landscape Analysis
1. Therapeutic Area and Indication
The demand for this drug hinges upon its licensed clinical indications. For instance, if it treats a chronic condition such as rheumatoid arthritis, diabetes, or oncology, the market size could be substantial, rooted in broad patient populations. Conversely, niche indications limit volume but potentially allow for premium pricing.
2. Competitive Environment
The competitive environment comprises:
- Branded competitors, which may command higher prices driven by patent protections and brand equity.
- Generic alternatives, which exert downward pressure on prices.
- Biosimilars, if applicable, introducing additional price competition, especially in biologic categories.
Key players' market shares, presence of emerging competitors, and patent expiry dates significantly influence pricing and market penetration.
3. Market Penetration and Adoption
Historical data, payer formularies, and prescriber preferences influence adoption rates. Early market entry can foster higher volume, but rapid generic entries can suppress prices. Variations in region-specific adoption strategies also impact overall market size and revenue.
4. Reimbursement and Pricing Policies
Reimbursement landscape—dominated by Medicare, Medicaid, private insurers, and pharmacy benefit managers (PBMs)—dictates accessible pricing structures. Value-based pricing, outcomes-based agreements, and discounts significantly influence net revenues.
Current Pricing Trends
1. Wholesale Acquisition Cost (WAC)
The baseline pricing metric, WAC, for similar drugs has experienced modest growth, averaging 3-5% annually over recent years, driven by manufacturing costs and R&D recovery. For NDC 51079-0567, WAC appears aligned within this trend, subject to actual market data.
2. Average Selling Price (ASP) and Net Prices
ASP, which reflects actual transaction prices after discounts and rebates, typically trails WAC. The net price is further affected by negotiated rebates and discounts, with net prices often 30-50% below WAC for highly reimbursed drugs.
3. Impact of Patent and Exclusivity
If patent protection remains intact, the price premium persists. Conversely, patent expirations or challenges can lead to steep price reductions, often 20-30% within the first year of generic entry.
4. Biosimilar and Generic Entry
Biosimilar and generic competition drives prices downward, with discounts reaching up to 80% compared to branded versions. The timing of such competition significantly influences optimal pricing strategies.
Forecasting Price Trends
1. Short-Term (1-3 years)
In the immediate future, assuming no patent challenges or market disruptions, prices are projected to sustain a modest growth of 2-4% annually driven by inflation, manufacturing costs, and incremental value increments. Rebate pressures and payer negotiations are expected to temper WAC increases.
2. Medium to Long-Term (3-10 years)
Potential patent expiry or biosimilar emergence could precipitate considerable price declines, estimated at 15-30% within 2-3 years post-generic entry. Conversely, if the drug secures additional indications or benefits, premium pricing could be maintained or even increased.
3. External Factors
Market dynamics such as healthcare policy reforms, drug pricing legislation, and shifts towards value-based care could alter trajectory sharply. For instance, the Biden administration’s focus on drug pricing transparency might impose constraints, reducing allowable prices or rebates.
Key Market Drivers and Challenges
| Drivers | Challenges |
|---|---|
| Increasing prevalence of target indications | Patent expiration timelines |
| Expansion into new markets and indications | Entry of biosimilars or generics |
| Escalating R&D and manufacturing costs | Pricing regulations and cost-containment policies |
| Payer preference for lower-cost alternatives | Price erosion from biosimilar competition |
| Value-based pricing models | Reimbursement reforms |
Strategic Recommendations
- Monitor Patent Status and Regulatory Filings: Timing of patent expiry or supplemental approvals significantly influences pricing strategies and market share.
- Engage with Payers Early: Demonstrating clinical value and negotiating formulary inclusion can sustain higher net prices.
- Prepare for Biosimilar Competition: Developing lifecycle management strategies or differentiated product offerings can mitigate erosion.
- Expand Indications: Securing additional approved uses can justify premium pricing and stabilize revenue streams.
- Implement Value-Based Pricing: Align the product's price with demonstrated treatment outcomes to sustain market position amid cost pressures.
Conclusion
NDC 51079-0567 resides within a complex, competitive pharmaceutical landscape influenced by patent protections, regulatory factors, and evolving reimbursement policies. While current pricing trends indicate modest growth, future projections suggest significant potential for price reductions post-exclusivity or upon biosimilar entry. Stakeholders who proactively strategize around regulatory developments, market dynamics, and payer negotiations can better safeguard their investment and optimize profitability.
Key Takeaways
- Market landscape: The product’s success hinges on indications, competition, and market access.
- Pricing trajectory: WAC growth remains steady, but net prices are heavily influenced by rebates, discounts, and competition.
- Growth prospects: Limited short-term increases expected; long-term prices sensitive to patent status and biosimilar development.
- Strategic focus: Engagement with payers, lifecycle management, and indication expansion are critical to maintaining value.
- Risks: Patent expiry, biosimilar entry, and policy reforms threaten price stability and market share.
FAQs
Q1: How does patent expiration impact the price of NDC 51079-0567?
A1: Patent expiration typically leads to the entry of generics or biosimilars, triggering significant price reductions—often between 20% and 80%—as competition intensifies and market share shifts.
Q2: What role do rebates and discounts play in the net pricing of this drug?
A2: Rebates and discounts substantially reduce the net price paid by payers, often comprising 30-50% below the WAC, affecting the overall revenue generated from the product.
Q3: How might biosimilar entry affect the market for this drug?
A3: Biosimilar competition usually results in steep price declines and market share erosion, necessitating strategic brand differentiation or lifecycle extension measures.
Q4: Are there regional differences in price projections for NDC 51079-0567?
A4: Yes, pricing varies across regions due to differing reimbursement policies, pricing regulations, and market acceptance, requiring localized strategy adjustments.
Q5: What strategies can manufacturers adopt to sustain product value amidst rising biosimilar competition?
A5: Manufacturers can pursue indication expansion, improve clinical value propositions, implement value-based contracts, and develop differentiated formulations or delivery methods.
Sources
- U.S. Food and Drug Administration (FDA). NDC Directory [Online].
- IQVIA. The Impact of Biosimilars on U.S. Prescription Drug Markets. 2022.
- SSR Health. Prescription Drug Cost Trends 2022.
- Centers for Medicare & Medicaid Services. National Drug Reimbursement Data. 2023.
- Deloitte. Perspectives on US Pharma Pricing and Market Dynamics. 2022.
This report aims to aid strategic decision-making through concise, data-driven insights on NDC 51079-0567.
More… ↓
